SCIENCE@home

Efficacy of combined varenicline and nicotine replacement therapy compared with varenicline or nicotine replacement therapy alone for smoking cessation: A systematic review and meta‐analysis

Xinmei Zhou,Zhenxiao Huang,Qingqing Song,Xin Xia,A. Cheng,Zhao Liu,Min Wang,Tingfen Ji,Ailifeire Aihemaiti,Ying Xie,Yi Liu,Yuxin Shi,Shunyi Shi,Yingman Gao,Hang Liu,Jiahui He,Liang Zhao,Dan Xiao,Chen Wang

Published 2025 in Addiction

ABSTRACT

Abstract Aims To assess whether combining nicotine replacement therapy (NRT) with varenicline improves long‐term smoking cessation rates compared with varenicline or NRT alone. Method Systematic review and meta‐analysis of randomized controlled trials (RCTs) or quasi‐RCTs, conducted according to PRISMA guidelines. A comprehensive literature search of PubMed, MEDLINE, EMBASE, Web of Science and the Cochrane Central Register of Controlled Trials was conducted through June 2025. The primary outcome was smoking abstinence at the longest follow‐up (≥6 months). Secondary outcomes included adverse events (AEs) and serious adverse events (SAEs). Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using random‐effects meta‐analyses. The certainty of evidence was assessed using the GRADE approach. Risk of bias was assessed using the Cochrane RoB 2.0 tool. The protocol was pre‐registered in the PROSPERO (registration number CRD42024600510). Results Seven trials including 2631 participants met inclusion criteria. Compared with varenicline alone, combination therapy was associated with statistically significantly higher abstinence rates at the longest follow‐up (RR = 1.33, 95% CI = 1.04–1.69; 5 studies; I2 = 51%). A sensitivity analysis including trials with ≥3 months of follow‐up yielded similar results (RR = 1.31, 95% CI = 1.06–1.62; 6 studies). However, when excluding the trial at high risk of bias, the result was not statistically significant (RR = 1.26, 95% CI = 0.94–1.68). Compared with NRT alone, only one RCT was included, and the effect of combination therapy on abstinence was not statistically significant (RR = 0.94, 95% CI = 0.51–1.72). AEs were more common with combination therapy compared with varenicline alone (RR = 1.11, 95% CI = 1.02–1.20). Specifically, skin reactions were significantly increased with NRT patch plus varenicline (RR = 1.67; 95% CI = 1.29–2.16). Compared with NRT alone, combination therapy was associated with increased AEs (RR = 1.23; 95% CI = 1.07–1.41). SAEs were infrequent and generally unrelated to treatment. Conclusions Low‐certainty evidence indicates that combining varenicline with nicotine replacement therapy may improve long‐term smoking cessation rates compared with varenicline alone and is generally well tolerated.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-48 of 48 references · Page 1 of 1

CITED BY